Anaplastic Thyroid Cancer – Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

1.1. ReportOverview

2. Anaplastic Thyroid Cancer - Overview

3. Executive Summary

4. Anaplastic Thyroid Cancer : Pipeline Assessment

4.1. By Stage ofDevelopment

4.2. By Route ofAdministration

4.3. By DrugClass

4.4. By MoleculeType

4.5. By TherapyArea / Indication

4.6. By DrugTarget

4.7. By Sponsor

5. Anaplastic Thyroid Cancer: Company & Drug Profiles

5.1. ClinicalStage

5.1.1. Lenvatinib – Translational Research Center forMedical Innovation, Kobe, Hyogo, Japan

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status & Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. Docetaxel – Mayo Clinic

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status & Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. Durvalumab – Memorial Sloan Kettering CancerCenter

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status & Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2. Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status & Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Anaplastic Thyroid Cancer: An Overview on Dormant & DiscontinuedPipeline Candidates

6.1. Overview

6.2. ProductDescription

6.3. Reason forDiscontinuation

7. Anaplastic Thyroid Cancer: Additional Key Insights

7.1.Epidemiology Overview: Anaplastic Thyroid Cancer

7.2. CurrentMarket Scenario: Anaplastic Thyroid Cancer Therapeutics

8. Anaplastic Thyroid Cancer: News, Press Releases and ConferenceDetails

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.